Letrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy

Ovarian Hyperstimulation Syndrome (OHSS) is an uncommon but serious complication occurring in patients undergoing ovarian stimulation. It is characterized by ovarian enlargement, nausea, vomiting, abdominal pain/distension, and reduction in urine output. However, OHSS may rarely evolve into a life-threatening condition with ascites, hemoconcentration and hypercoagulability. Prevention of OHSS consists of an integrated approach that associates behavioral aspects with administration of pharmacological compounds. Among drugs used to manage OHSS, Letrozole has recently been proposed as an effective option for prevention of the syndrome. However, despite the promising findings reported by several studies, to date Letrozole is not yet officially mentioned in the guidelines for Prevention and Treatment of moderate and severe ovarian hyperstimulation syndrome. In this scenario, the current study discusses Letrozole approaches scientifically available to prevent OHSS.

Automated summary

Ovarian Hyperstimulation Syndrome (OHSS) is a serious complication in ovarian stimulation treatment, characterized by ovarian enlargement and various symptoms. Letrozole has shown potential as an effective preventive option for OHSS, although it is not yet officially recommended in guidelines. This study discusses the scientific approaches of using Letrozole to prevent OHSS.